International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1007-1015 www.ijprajournal.com ISSN: 2456-4494

"Enhancing Anticoagulation Safety in Atrial Fibrillation: Targeted Strategies for Better Outcomes"

Sincy Ann Sebastian[1*], Sriram R.[1], Sruthi R.[1], Dr. J. Sam Johnson Udaya Chandar[2]

[1]*PharmD Intern,* [2] *Assistant Professor*

Department of Pharmacy Practice, College of Pharmacy, Sri Ramakrishna Institute Of Paramedical Sciences, Coimbatore – Tamil Nadu

---

Date of Submission: 10-12-2024 Date of Acceptance: 20-12-2024

ABSTRACT: Our following study has four objectives, (i) assessing prescribing patterns for anticoagulants, (ii) evaluating the application of bleeding risk assessment tools to identify patient specific factors influencing anticoagulation safety, (iii)analysing the effectiveness of pharmacist-driven strategies, (iv) examining the impact of interventions on clinical outcomes.The methodology involves conducting a systemic review of studies that examine the safety and prescribing practices of anticoagulants across various patient populations with atrial fibrillation. Data is collected to identify common prescribing errors, dosing patterns, and bleeding complications. The study then emphasizes how structured pharmacist-led interventions can improve prescribing accuracy and patient safety, thereby playing a critical role in optimizing anticoagulation therapy.The outcome of pharmacist-led interventions in anticoagulation therapy shows a marked improvement in patient safety and clinical outcomes, such as reduction in dosing errors and bleeding complications. Individualised dosing strategies tailored to factors such as renal functions and other comorbidities, improves therapeutic outcomes and minimizes risks. Accuracy of prescribing and better patient compliance has been shown due to pharmacists' involvement in medications reviews, patient education and dose adjustments. Structured anticoagulation management programs, such as remote care options, helps to improve access to care, and maintain continuous monitoring.Pharmacist-led interventions play a critical role in optimizing anticoagulation therapy, improving the accuracy of dosing, and reducing bleeding risk and other adverse events in patients on anticoagulants. The integration of personalized management and structured anticoagulation programs proves to enhance patient safety and drug efficacy. Future research should focus on refining these interventions for diverse patient populations and investigate genetic factors for more precise anticoagulation management.

KEYWORDS: Bleeding, Anticoagulant, Atrial fibrillation, Cardiovascular, Prescribing

I. INTRODUCTION

What Is Atrial Fibrillation?

[1] Atrial fibrillation is characterized as tachyarrhythmia, which is one of the most common type of cardiac arrhythmia. It is caused by the abnormal electrical activity within the atria of the heart. Due to the irregularity of its rhythm, the flow of blood through the heart becomes turbulent thereby elevating the chance of a thrombus formation(blood clot), which can break loose and cause a stroke. Advanced age, high blood pressure, underlying heart and lung disease, congenital heart disease, and increased alcohol consumption are some risk factors of atrial fibrillation. Symptoms of atrial fibrillation include chest pain, palpitations, fast heart rate, shortness of breath, nausea, dizziness, diaphoresis, and generalized fatigue, etc.

Burden of Atrial Fibrillation

[2] Atrial fibrillation (AF) is a worldwide public health issue, where its epidemiological patterns have changed globalover the decades. Multiple factors, such as genetics, biological, and environmental variables were found to have a high impact on the increased hospitalizations for atrial fibrillation/ atrial flutter. During the past three decades, the global prevalence and incidence of AF have increased despite improvements and innovations in AF treatment. The prevalence and incidence of AF were found to vary in various nations due to several variables, such as age, body

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1007-1015 www.ijprajournal.com ISSN: 2456-4494

mass index, gender, smoking, use of alcohol, genetic condition, socioeconomic level, and education.

[2] In 2019, the incident number of AF had a progressive increase of 104.03% globally, with an estimated 4.72 million since 1990. AF also accounted for 8.39 million disability-adjusted life years (DALYs), 0.32 million deaths, and 59.70 million prevalent cases. The results furthermore indicated that males under the age of 70 years had a higher incidence, prevalence, and DALYs than females. The rates were found to be similar for both genders between the age group of 70 and 74 years.This pattern was however reversed in individuals over the age of 75, as females were showing a higher total prevalence, incidence, and DALYs than males. The socio-demographic index (SDI) increased with an increase of age-standardized rates (ASRs) of prevalence, incidence, mortality, and DALYs.High systolic blood pressure, high body-mass index, and smoking were the three primary contributors to AF

Global Burden of Atrial Fibrillation in India

[3] Through systematic screening, the estimates of AF prevalence of the general population range from 0.54% to 4.4%. These studies included participants above the age of 30 years. In all the studies, the mean age of the participants was above 50 years, an age group where the prevalence of AF is plausibly high. Compared to studies from the developed countries, the prevalence of AF is lower (0.3%).

[4] Another screening study done in an urban area in Nagpur (with 4,077 urban adults)discovered the prevalence of AF to be 0.2% after 12-lead ECGs were performed, which was corresponding to global AF prevalence estimates. [3] An additional study, the SMART-AF study, was a systematic population-based study conducted in a rural area in the state of Gujarat (North-West India), which showed AF prevalence of 1.6%.

[3] In a cross-sectional survey of a general population in rural South India, which investigated the prevalence and risk factors of AF, stroke risk and prophylaxis against stroke, the following study findings were discovered: (i) The prevalence of AF was found to be 0.3% using a smart phone-based ECG device (ii) 13 out of 14 patients with AF were non-valvular AF (iii) 10 out of 13 patients with NVAF had a CHA_2DS_2-VASc score of ≥ 2

Treatment of Atrial Fibrillation

[5] Atrial fibrillation (AF) is an enormous burden worldwide because of the high rates of morbidity, disability and mortality. Recently, increasing evidence and advancements in medical technology have helped us gain a clearer awareness of AF. Therefore, management of AF has developed gradually in the past few years, so as to improve prevention and control of AF. Current therapy of atrial fibrillation mainly includes drug therapy, cryoballoon ablation, catheter ablation, the maze procedure, and left atrial appendage closure. The three major drug treatment strategies for AF are rhythm control, rate control and prevention of stroke. Recent research has also call attention to the favourable effects of lifestyle and risk-factor management for atrial fibrillation as upstream therapy.

Projectile Of Atrial Fibrillation

[6] From 1990 to 2019, the global prevalence of AF has doubled, arriving at 59.7 million cases in 2019. Atrial fibrillation affects 3–5 million individuals and is estimated to increase to over 8 million by 2050 due to population aging in the USA. The prevalence is foreseen to spurt from 8.8 million to 18 million by 2060 in Europe. [7] AF incidence will double from 1.2 million cases in 2010 to 2.6 million cases in 2030. Given this increase in incidence, AF prevalence is projected to increase from 5.2 million in 2010 to 12.1 million cases in 2030. [8]In Asia, atrial fibrillation has become a health burden. In the year 2050, Asia is estimated to have 72 million AF patients, and 2.9 million within them will suffer from AF-associated stroke.

II. METHODOLOGY

The study examined numerous articles exploring prescribing practices, safety considerations, and the management of Direct Oral Anticoagulants (DOACs), with a focus on preventing complications such as bleeding and thromboembolic events, especially in patients with atrial fibrillation or complex comorbid conditions. The methodology involved:

1. **Literature Review**: Reviewing studies across varied patient population, types of DOACs, and bleeding risk assessment scores.
2. **Evaluation of Interventions**: Evaluating pharmacist-led strategies for dose adjustments, patient education, and medication reviews to improve prescribing practices and mitigate risks.
3. **Outcome Analysis**: Analysing clinical outcomes such as bleeding complications,

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1007-1015 www.ijprajournal.com ISSN: 2456-4494

adverse drug events, and efficacy of anticoagulation therapy.

The study employed a comprehensive review of research articles centered on the prescribing practices, safety, and management of Direct Oral Anticoagulants (DOACs). These studies explored a range of patient populations, including individuals with atrial fibrillation, renal impairments, and various comorbidities. The review examined the prevalence of prescribing errors, including underdosing and overdosing, and evaluated the associated risks, such as bleeding and thromboembolic complications. In addition, the studies utilized bleeding risk assessment tools, like the HAS-BLED score, to assess patient-specific factors that impact anticoagulation therapy. Special emphasis was placed on pharmacist-led interventions, such as medication reviews, dose modifications, deprescribing unsuitable medications, and patient education initiatives. In summary, the methodology emphasized exploring how structured interventions can improve prescribing accuracy and patient safety, while also highlighting the significant role of pharmacists in minimizing adverse events and optimizing outcomes in anticoagulation therapy.

III. RESULTS AND DISCUSSION

Atrial fibrillation (AF) is a type of cardiac arrhythmia. Due to the formation of blood clots in the atria, it significantly increases the risk of stroke and thromboembolic events. Anticoagulation therapy helps to avert from these complications by reducing blood clot formation. Appropriate dosing of anticoagulants of utmost importance because both under- and overdosing can lead to bleeding, stroke, and other such adverse events. Anticoagulation therapy can be optimized by personalized treatment adjustments, regular monitoring with the aid of pharmacist –led interventions

The articles reviewed focus on the safety, prescribing practices, and management of Direct Oral Anticoagulants (DOACs) across various patient populations, with a target to prevent complications of bleeding, labelling common prescribing errors, and pharmacist-led intervention strategies among patients with conditions necessitating anticoagulation therapy. These studies extend over patient demographics, types of DOACs administered, and bleeding risk assessment scores, focusing to understand the effects of anticoagulation therapy on outcomes, particularly in older patients or those with atrial fibrillation (Refer Table no.1).

A primary concern identified across studies is inappropriate dosing, especially in patients with renal impairment or those with complex comorbidities, which can increase the risk of adverse events such as bleeding. Pharmacist-led interventions emerged as a critical strategy for improving the safety and appropriateness of DOAC prescribing. Pharmacists played a role in several studies by identifying and rectifying the prescribing errors, conducting medication reviews and providing patient education. For example, a study by Ting et al. (2021) showed that patients with moderate to severe renal impairment were often prescribed incorrect DOAC doses, with interventions including dose adjustments or drug discontinuation. In another study, Li et al. (2020) evaluated a pharmacist-led outpatient service for geriatric patients on rivaroxaban, discovering that such interventions helped reduce bleeding complications compared to routine care. Similarly, Domaleczny et al. (2022) highlighted the importance of pharmacist involvement in deprescribing inappropriate aspirin therapy in patients on anticoagulants, which significantly lowered drug-related problems. Other studies also highlighted issues with concurrent drug interactions, particularly when DOACs were prescribed alongside antiplatelet therapy, thereby heightening the bleeding risks. These findings emphasizes the value of pharmacist-led services in enhancing patient outcomes and preventing any harm in anticoagulation therapy.

The key findings across these studies highlight drug selection error and anticoagulant prescribing error such as both underdosing and overdosing. The inappropriate dosing percentages vary widely depending on the anticoagulant used and patient bleed risk assessment (e.g. HAS-BLED scores. The data also reveals the gender disproportion, where a majority of the patients were male, and age distribution pattern, often with a median age of 70-83 years.

Pharmacist-led interventions, such as education and prescription reviews, appear to be effective in improving patient outcomes and reducing these risks associated with the use of anticoagulant drugs. This underscores the importance of involvement of pharmacists in anticoagulation management. For example, in a model of anticoagulation management, remote care and drive-up clinics were included during the COVID-19 pandemic, as face-to-face visits were limited. Sherwin et al. (2023) assessed the efficacy

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1007-1015 www.ijprajournal.com ISSN: 2456-4494

of a drive-up anticoagulation clinic, showing that it allowed continued monitoring and intervention while maintaining social distancing. Additionally, Dreijer et al. (2020) underscored the role of hospital-wide anticoagulation stewardship programs in improving both the safety and effectiveness of anticoagulation therapy. These programs often included patient counselling, medication reviews and the development of guidelines, which overall contributed to reducing major bleeding and thrombotic events. Collectively, these studies showcase the complexity of anticoagulation therapy and the essential role of clinical pharmacy services in managing these therapies safely.

Pharmacist led management appears to mitigate the risks in anticoagulation therapy, thereby highlighting the requirement for structured anticoagulation programs in clinical settings to optimize therapeutic outcomes. Future research could explore the efficacy of anticoagulation management models in miscellaneous populations. Investigating genetic markers for assessing the risk of bleeding or individual responses to anticoagulants may help further personalize anticoagulation therapy.

IV. CONCLUSION

Pharmacist-led interventions significantly enhance the safety and effectiveness of anticoagulation therapy by refining drug dosing, reducing complications, and ensuring better patient outcomes. These interventions aim to resolve key challenges, including inappropriate dosing, drug interactions, and gaps in patient education. Additionally, the study underscores the necessity of structured anticoagulation management programs to support high-risk populations, such as elderly patients and those with multiple comorbidities. The reviewed studies highlighted pharmacists' role in enhancing treatment by identifying prescribing errors, adjusting doses for patients with renal impairments, and discontinuing unnecessary medications. This highlights the importance of integrating pharmacists into the healthcare team to improve therapeutic outcomes and patient safety. Innovative approaches, including remote care models and hospital-wide stewardship programs proved effective in sustaining therapy even during challenging circumstances like the COVID-19 pandemic. Future research should investigate genetic markers and personalized treatment models to further enhance anticoagulation therapy. These findings emphasize the vital importance of multidisciplinary strategies and tailored interventions in mitigating risks and improving outcomes in anticoagulation management.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1007-1015 www.ijprajournal.com ISSN: 2456-4494

ARTICLE NAME	AGE	GENDER	ANTI-COAGULANT	BLEEDING RISK ASSESSMENT	MEDICAL ERROR	INTERVENTION
[10] Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment	MEDIAN AGE: 81 YEARS (75-87%)	MALE: 41-54% FEMALE: 46%-59%	DOAC (mostly rivaroxaban)	HAS BLED SCORE: For appropriate dosing: *<3:63% *>=3:37% For inappropriate dosing: *<3:21.6% *>=3:48.2%	*Inappropriate dosing *AE: Renal dysfunction, bleeding	1) DOAC dose change 2) DOAC discontinuation 3) Correcting the prescribing error
[11] Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation	≥18 years	FEMALE: 48.5% MALE: 51.5%	Dabigatran, Apixaban Rivaroxaban	HAS BLED SCORE: 2	*AE: Bleeding *Prescribing error	1)Change of drug 2)Stop aspirin/ Clopidogrel/ dual antiplatelet therapy 3)Adjust the DOAC dose
[12] Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions	≥18 years	FEMALE: 45.3% MALE: 54.7%	Rivaroxaban Apixaban Dabigatran Edoxaban	HAS BLED SCORE: 1.7 ± 0.98	Inappropriate prescribing of DOAC	Inappropriate dosage in prescription
[13] Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic	≥65 years	MALE: 60% FEMALE: 40%	Rivaroxaban	INR:1.1 PT time: 12.6 (usual care) 12.7 (intervention) PT > 13s, (%) 17.3(usual	*Bleeding complications within 90 days *GI haemorrhage *Hematuresis *Epidural hematoma	*Pharmacist-led education and follow-up service (PEFS) *Usual care (routine medication education after discharge)

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1007-1015 www.ijprajournal.com ISSN: 2456-4494

				care) 12.3 (intervention)	*Epistaxis *Operation site hemorrhage *Bleeding gums *Skin ecchymosis	
[14] A cross-sectional study of appropriateness evaluation of anticoagulation therapy for inpatients with nonvalvular atrial fibrillation	≤64: 15.5% 65–74: 29.7% ≥75: 54.9%	FEMALE : 43.7% MALE: 56.3%	NOACs	<3 score: 77.2% ≥3 score: 22.8%	Incorrect dosing of OACs	*Administer individualized anticoagulation regimens based on the patient's clinical data *Rectification of incorrect dosages and drug combinations during follow-up.
[15] Evaluation of a pharmacist-led drive-up anticoagulation clinic during the coronavirus 2019 pandemic	60 ± 16 yrs	MALE : 61.8% FEMALE : 38.2%	*Warfarin *DOAC	INR goal range, n (%): *2.0-3.0: (89.7%) *2.5-3.5: (10.3%)	Minor bleeding events (e.g., nosebleeds, blood in stool or urine, and excessive bruising)	Transitioning in-person care to drive-up clinics, where patients could receive care while socially distanced in their vehicle
[16] Impact of pharmacist intervention to deprescribe inappropriate aspirin therapy in an outpatient anticoagulation clinic at a community hospital	72.7 ± 8 yrs	34.7% female	Warfarin DOAC	NA	*Inappropriate aspirin prescribing	*Concurrent use of aspirin and indefinite OAC stopped. *Identify inappropriate aspirin therapy and discontinuation
[17] Drug-related problems associated with direct oral anticoagulants: an observational cross-sectional study of medical record review by pharmacists in a large teaching hospital	70 (±13) years	Male: 54% Female: 46%	DOAC (rivaroxaban, dabigatran, and apixaban).	NA	*Inappropriate drug regimen *Prescribing error (Drug interaction, therapeutic duplication, etc)	Renal dose adjustment for DOACs

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1007-1015 www.ijprajournal.com ISSN: 2456-4494

[18] The Role of Clinical Pharmacy Anticoagulation Services in Direct Oral Anticoagulant Monitoring	67-69years (mean)	62% Male 38%female	DOAC: Apixaban Rivaroxaban Dabigatran	CHA2DS2-VAS score: 2.7-3.0	*Bleeding *GIT bleeding	1) addressing inappropriate DOAC dosing, 2) addressing changes in renal function, 3) addressing bleeding concerns 4) evaluating potential DOAC treatment failures 5) developing periprocedural plans 6) managing drug interactions 7) addressing insurance coverage or cost issues 8) addressing adherence concerns 9) discontinuing DOAC therapy, 10) managing side effects other than bleeding, and 11) "other" types of interventions
[19] Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization	18 years and older Mean age(69 years)	Male : 60% Female : 40%	LMWH DOAC	NA	*Major bleeding *Non major bleeding *Thrombotic events	*Hospital-wide education was given. *Medication reviews by pharmacists *Antithrombotic therapy guidelines were drafted *Patient counselling *Medication

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 1007-1015 www.ijprajournal.com ISSN: 2456-4494

						reconciliation.
[20]Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription	Median age: 83yrs	FEMALE : 57%	DOAC LMWH UH (Unfraction. heparin)	NA	Inappropriate prescribing	*Dose adjustments *Drug interactions *Ordering laboratory testing *Initiation and interruption of anticoagulant *Verbal discussion *Dose adjustments of DOACs and VKAs.
[21]Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation	age ≥73yrs	56.1% Male	DOAC (Dabigatran, Apixaban, Rivaroxiban) Warfarin	CHAD-VAS Score:3	*Major bleeding *Thrombo-embolic stroke *intracranial hemorrhage *GI bleeding *Inappropriate prescribing of DOAC *Inadequate adherence with DOACs	Anticoagulation Management Care Models: *Usual care *UC plus an automated population management tool(PMT) *AMS (anticoagulation management services, i.e., warfarin clinics)

(TABLE NO.1)

REFERENCES

[1]. Nesheiwat Z, Goyal A, Jagtap M,et al. Atrial fibrillation [Internet]. National Library of Medicine. StatPearls Publishing; 2023.
[2]. Q, Zhu J, Zheng P, Zhang J, Xia X, Zhao Y, et al. Global burden of atrial fibrillation/flutter: Trends from 1990 to 2019 and projections until 2044. Heliyon. 2024 Jan 1;10(2):e24052–2.
[3]. Saggu DK, Rangaswamy VV, Yalagudri S, Sundar G, Reddy NK, Shah V, et al. Prevalence, clinical profile, and stroke risk of atrial fibrillation in rural Andhra Pradesh, India (the AP-AF study). Indian Heart Journal [Internet]. 2022 Mar 1 [cited 2023 Nov 30];74(2):86–90.
[4]. Saggu DK, Sundar G, Nair SG, Bhargava VC, Lalukota K, Chennapragada S, et al. Prevalence of atrial fibrillation in an urban population in India: the Nagpur pilot study. Heart Asia [Internet]. 2016 [cited 2022 Apr 27];8(1):56–9.
[5]. Li J, Gao M, Zhang M, Liu D, Li Z, Du J, et al. Treatment of atrial fibrillation: a comprehensive review and practice guide. Cardiovascular Journal of Africa [Internet]. 2020 Jul 2;31(3):45–50.
[6]. Cheng S, He J, Han Y, Han S, Li P, Liao H, et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021. EP Europace. 2024 Jul 1;26(7).
[7]. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. et al Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. The American Journal of Cardiology. 2013 Oct;112(8):1142–7.
[8]. Chiang CE, Wang KL, Lin SJ.et al Asian strategy for stroke prevention in atrial

fibrillation. Europace. 2015 Oct;17(suppl 2):ii31–9.

[9]. Soni A, Earon A, Handorf A, Fahey N, Talati K, Bostrom J, et al. High Burden of Unrecognized Atrial Fibrillation in Rural India: An Innovative Community-Based Cross-Sectional Screening Program. JMIR Public Health and Surveillance [Internet]. 2016 Oct 13 [cited 2021 Mar 6];2(2):e6517

[10]. Ting C, Rhoten M, Dempsey J, Nichols H, Fanikos J, Ruff CT. Evaluation of direct oral anticoagulant prescribing in patients with moderate to severe renal impairment. Clinical and Applied Thrombosis/Hemostasis. 2021 Jan 1;27.

[11]. Raccah BH, Erlichman Y, Pollak A, Matok I, Muszkat M. Prescribing errors with direct oral anticoagulants and their impact on the risk of bleeding in patients with atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics. 2021 Jun 1;26(6):601–10.

[12]. Zhang ZX, van de Garde EM, Söhne M, Harmsze AM, van den Broek MP. Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions. British Journal of Clinical Pharmacology. 2020 Mar 13;86(8):1567–74.

[13]. Li X, Zuo C, Lu W, Zou Y, Xu Q, Li X, et al. Evaluation of remote pharmacist-led outpatient service for geriatric patients on rivaroxaban for nonvalvular atrial fibrillation during the COVID-19 pandemic. Frontiers in Pharmacology. 2020 Aug 21;11

[14]. Zheng X-Y, Feng G-W, Guo J, Xie F, Li X, Zhang M-Z, et al. A cross-sectional study of appropriateness evaluation of anticoagulation therapy for inpatients with nonvalvular atrial fibrillation. Frontiers in Pharmacology. 2023 Dec 5;14.

[15]. Sherwin E, Schaefer M, Huffmyer M, Naseman K, Davis GA, Schadler A, et al. Evaluation of a pharmacist-led drive-up anticoagulation clinic during the coronavirus 2019 pandemic. Journal of the American Pharmacists Association. 2023 Jan;63(1).

[16]. Domaleczny BJ, Lewis SJ, Richardson JL, Eid HR. Impact of pharmacist intervention to deprescribe inappropriate aspirin therapy in an outpatient anticoagulation clinic at a Community Hospital. American Heart Journal Plus: Cardiology Research and Practice. 2022 May;17:100165.

[17]. Chow MMY, Chua DJJ, Wong VSY, How SY, Koh SK, Tay XY, et al. Drug-related problems associated with direct oral anticoagulants: An observational cross-sectional study of medical record review by pharmacists in a large teaching hospital. Research and Practice in Thrombosis and Haemostasis. 2024 Feb;8(2):102354.

[18]. Jones AE, King JB, Kim K, Witt DM. The role of Clinical Pharmacy anticoagulation services in direct oral anticoagulant monitoring. Journal of Thrombosis and Thrombolysis. 2020 Feb 21;50(3):739–45.

[19]. Dreijer AR, Kruip MJ, Diepstraten J, Polinder S, Brouwer R, Mol PG, et al. Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization. PLOS ONE. 2020 Jun 25;15(6).

[20]. Koolian M, Wiseman D, Mantzanis H, Kampouris N, Kerzner RS, Kahn SR. Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription. Research and Practice in Thrombosis and Haemostasis. 2022 Aug;6(6).

[21]. Derington CG, Goodrich GK, Xu S, Clark NP, Reynolds K, An J, et al. Association of Direct Oral Anticoagulation Management Strategies with clinical outcomes for adults with atrial fibrillation. JAMA Network Open. 2023 Jul 6;6(7).